Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OVX836 Immunogenicity and Safety Study
NCT06582277Phase 2Completed
- Sponsor
- Osivax
- Start
- Oct 2024
- Primary completion
- Jun 2025
- Modality
- Nanoparticles, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of OVX836 in influenza, sponsored by Osivax. Started Oct 2024; status: completed.
02
Drugs
OVX836
03
Conditions
influenza
Beyond the preview
Go deeper on NCT06582277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06582277.